Bone morphogenetic protein sales will strengthen through 2036, anchored by rhbmp-2 at 55.1% of the type segment in 2026, driven by established clinical adoption and regulatory approval for orthopedic procedures. The market was valued at USD 358.0 million in 2025 and is expected to be worth USD 605.92 million by 2036.